263 related articles for article (PubMed ID: 30154192)
1.
Frank MJ; Reagan PM; Bartlett NL; Gordon LI; Friedberg JW; Czerwinski DK; Long SR; Hoppe RT; Janssen R; Candia AF; Coffman RL; Levy R
Cancer Discov; 2018 Oct; 8(10):1258-1269. PubMed ID: 30154192
[TBL] [Abstract][Full Text] [Related]
2. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD; Ai WZ; Czerwinski DK; Torchia JA; Levy M; Advani RH; Kim YH; Hoppe RT; Knox SJ; Shin LK; Wapnir I; Tibshirani RJ; Levy R
J Clin Oncol; 2010 Oct; 28(28):4324-32. PubMed ID: 20697067
[TBL] [Abstract][Full Text] [Related]
3. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.
Kim YH; Gratzinger D; Harrison C; Brody JD; Czerwinski DK; Ai WZ; Morales A; Abdulla F; Xing L; Navi D; Tibshirani RJ; Advani RH; Lingala B; Shah S; Hoppe RT; Levy R
Blood; 2012 Jan; 119(2):355-63. PubMed ID: 22045986
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis.
Shree T; Haebe S; Czerwinski DK; Eckhert E; Day G; Sathe A; Grimes S; Frank MJ; Maeda LS; Alizadeh AA; Advani R; Hoppe RT; Long SR; Martin B; Ozawa MG; Khodadoust MS; Ji HP; Levy R
Blood Adv; 2024 Jan; 8(1):130-142. PubMed ID: 37939259
[TBL] [Abstract][Full Text] [Related]
6. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
[TBL] [Abstract][Full Text] [Related]
8. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma.
Chan EK; Fung S; Gospodarowicz M; Hodgson D; Wells W; Sun A; Pintile M; Tsang RW
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e781-6. PubMed ID: 21167657
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
12. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Camisaschi C; Filipazzi P; Tazzari M; Casati C; Beretta V; Pilla L; Patuzzo R; Maurichi A; Cova A; Maio M; Chiarion-Sileni V; Tragni G; Santinami M; Vergani B; Villa A; Berti E; Umansky L; Beckhove P; Umansky V; Parmiani G; Rivoltini L; Castelli C
Cancer Immunol Immunother; 2013 May; 62(5):897-908. PubMed ID: 23589107
[TBL] [Abstract][Full Text] [Related]
13. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
14.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
Redfern CH; Guthrie TH; Bessudo A; Densmore JJ; Holman PR; Janakiraman N; Leonard JP; Levy RL; Just RG; Smith MR; Rosenfelt FP; Wiernik PH; Carter WD; Gold DP; Melink TJ; Gutheil JC; Bender JF
J Clin Oncol; 2006 Jul; 24(19):3107-12. PubMed ID: 16754937
[TBL] [Abstract][Full Text] [Related]
16. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
Saleh K; Michot JM; Schernberg A; Lazarovici J; Chahine C; Danu A; Khalife-Saleh N; Rossignol J; Ghez D; Martin V; Mazeron R; Fermé C; Boros A; Ribrag V; Girinsky T
Cancer Med; 2020 Jun; 9(11):3725-3732. PubMed ID: 32249547
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up and management of small and medium-sized CD4
Virmani P; Jawed S; Myskowski PL; Horwitz S; Skripnik Lucas A; Moskowitz A; Pulitzer M; Zain J; Rosen ST; Querfeld C
Int J Dermatol; 2016 Nov; 55(11):1248-1254. PubMed ID: 27369070
[TBL] [Abstract][Full Text] [Related]
19. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.
Zhang H; Liu L; Yu D; Kandimalla ER; Sun HB; Agrawal S; Guha C
PLoS One; 2012; 7(5):e38111. PubMed ID: 22666458
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
